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dress sample collection, protein extraction and fractionation, mass spectrometry modalities,
and quantitative proteomics. Finally, we examine the limitations and further potential of such
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etry-based proteome elucidation can reveal potential biomarkers and aid in the development
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Proteomics entails the characterization
of the complete set of proteins encoded by
the genome of a given organism in a given
state [1]. A cornerstone of proteomics is the
ability to perform sensitive mass spectro-
metric analysis on a complex mixture of pro-
teins  and  peptides.  Whereas  traditional
techniques have focused on only a few tar-
geted proteins per analysis, proteomics at-
tempts to conduct the comprehensive study
of complex protein mixtures and can identify
hundreds or thousands of proteins for future
investigation [2]. Proteomics can address
challenges that cannot be approached by ge-
nomic analysis, namely, relative abundance
of the protein products, post-translational
modifications,  compartmentalization,  and
turnover, as well as protein interactions and
protein function. In addition, the proteomic
analysis of human body fluids and tissues
can be a valuable approach in the search for
diagnostic and prognostic biomarkers. For
example, the acquisition of body fluids has
potential advantages of being relatively non-
invasive, economical, and easily collected. If
readily  available,  proximal  body  fluids,
which bathe the organ of interest, also have
the benefit of being rich in secreted proteins,
which are likely to include markers of dis-
eases affecting that particular organ.
One gene may produce more than one
protein, such as a genome of 30,000 genes can
produce more than 100,000 proteins, when al-
ternative splicing is considered [3]. In addition,
post-translational modifications occurring in
cells, such as phosphorylation and glycosyla-
tion, further expand the number of possible
protein isoforms to be identified [4,5]. Chal-
lenges related to the complexity of clinical
samples to be investigated may be overcome
by the development of standardized sample
preparation and handling protocols. Modern
peptide mass spectrometry, performed follow-
ing liquid chromatography fractionation, is
very well suited for handling mixtures of hun-
dreds or thousands of proteins. 
Below, we provide an overview of vari-
ous mass spectrometry-based proteomic tech-
niques that are applicable to the study of
translational medicine (Figure 1). We begin
with a qualitative assessment of the proteins
in a particular sample, covering the principles
of sample collection, protein extraction, and
fractionation. We then follow the innovations
through the current state of quantitative pro-
teomics. Finally, we comment on the poten-
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Figure 1. General workflow for mass spectrometry sample processing. Human body
fluids may be processed for mass spectrometry-based proteomic analysis using ap-
proaches including, but not limited to, those listed in the workflow diagram.tial of mass spectrometry-based proteomic
technologies to investigate clinical samples.
GEnERAL WORKFLOW
Sample collection
Consistent sample processing, collec-
tion, and analysis strategies must be estab-
lished  to  develop  reproducible  clinical
proteomics assays. Often in translational re-
search, there are insufficient standardized
protocols  regarding  specimen  collection,
storage, and processing. Significant changes
in the proteomic profile also may be intro-
duced during sample preparation if consen-
sus methodology is not in place. We realize
that variability cannot be entirely avoided;
however, it may be kept to a minimum by
careful and standardized sample handling.
Protein extraction
As the collected samples are to be pre-
pared for proteomic analysis, proteins should
be  extracted  from  lipids,  metabolites,  and
other non-proteinaceous compounds, which
may interfere with downstream procedures. In
general,  salt  removal  is  accomplished  via
methods such as dialysis (spin, micro) [6], ul-
trafiltration [7,8], gel filtration/electrophore-
sis, precipitation with acid or organic solvents,
and/or solid-phase extraction. Various chemi-
cal precipitation methods are available for
protein  isolation;  these  include  acetone,
trichloroacetic  acid  (TCA),  ethanol,  iso-
propanol, chloroform/methanol, and ammo-
nium  sulfate.  The  efficiency  of  protein
precipitation varies among different organic
solvents. For example, acetone has been de-
termined to precipitate more acidic and hy-
drophilic proteins, whereas ultracentrifugation
fractionates  more  basic,  hydrophobic,  and
membrane proteins [9]. Alternatively, chloro-
form methanol extraction has been used to
successfully  extract  hydrophobic  proteins
[10]. It is important that precipitation strate-
gies be optimized for a particular sample type. 
Protein fractionation
Following protein extraction, various
approaches can be used to fractionate pro-
teins prior to mass spectrometry analysis.
Fractionation can be performed either at the
protein level prior to proteolytic digestion or
at the peptide level following proteolytic di-
gestion. Below, we describe several meth-
ods that can be used for fractionation of
proteins from clinical samples prior to di-
gestion. All methods described in this sec-
tion  have  the  advantage  of  removing
additional  non-proteinacious  compounds
that remain after protein extraction and may
interfere with downstream analysis while si-
multaneously simplifying the protein mix-
ture to be further processed. These methods
can be implemented individually or in tan-
dem, according to sample complexity and
the depth of analysis required.
Gel-based fractionation
One-dimensional SDS-PAGE. Sodium
dodecyl  sulfate  polyacrylamide  gel  elec-
trophoresis (SDS-PAGE) fractionates proteins
according to electrophoretic mobility, an ap-
proximation of the molecular weight of the
proteins. The proteins are denatured first by
SDS, a strong ionic detergent, and heat. Disul-
fide bonds are reduced (commonly with DTT
(dithiothreitol)  or  TCEP  (tris(2-car-
boxyethyl)phosphine))  and  then  alkylated
(typically with iodoacetamide or acrylamide)
to prevent bond reformation. This solubilized
protein mixture is loaded onto the gel, and
upon application of an electric field, proteins
travel  through  the  polyacrylamide  matrix
forming distinct bands. These bands can be vi-
sualized  by  conventional  stains  such  as
Coomassie brilliant blue [11] and silver stain
[12], or fluorescent staining such as SYPRO
Ruby [13] and Deep Purple Total Protein
Stain [14]. Mass spectrometry-based tech-
niques coupled with in-gel tryptic digestion
can identify proteins present in Coomassie- or
silver-stained gel bands. For this approach, it
is advantageous to have the fewest number of
proteins in a sample. Sample complexity may
be  reduced  prior  to,  or  following,  elec-
trophoresis by further sample fractionation. 
Isoelectric focusing. Proteins (or pep-
tides) may be fractionated according to their
isoelectric  points  (pI).  The  most  common
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focusing (IEF), which separates molecules by
their intrinsic charge differences. In IEF, pro-
teins are loaded onto a medium on which a pH
gradient has been created by amphoteric mol-
ecules (ampholytes) that have both acidic and
basic groups. An electric current is passed
through the medium, producing positively and
negatively charged ends. Negatively charged
proteins migrate through the pH gradient to-
ward the positive end (anode), while positively
charged proteins move toward the negative
end (cathode) of the medium. The proteins are
ultimately focused around the pH that is equal
to their respective pI, at which point the protein
has no net charge and thus no longer migrates
in an electric field. Proteins now can be stained
or identified using gel-based mass spectrome-
try techniques or separated further according
to mass by overlaying the IEF medium onto
an SDS-PAGE slab [15]. 
Alternatively, recently developed OFF-
GEL fractionation (Agilent Technologies)
allows for the collection of peptides and pro-
teins in liquid fractions, which does not re-
quire protein/peptide extraction from the gel
matrix for downstream applications [16,17].
During OFF-GEL fractionation, samples are
added into buffer compartments over an IPG
strip. Peptides then migrate through the gel
strip and can be collected in solution from
the appropriate buffer compartment without
the need of extracting from the gel strip.
Similar to standard IEF, OFF-GEL fractions
can be analyzed further by separation in a
second dimension or digested in-solution for
mass spectrometry analysis. 
Similarly, capillary electrophoresis (CE)
or capillary zone electrophoresis (CZE) of-
fers an alternative gel-free method to sepa-
rate peptides and proteins. CE can separate
ionic species by their charge, hydrodynamic
radius, and frictional forces [18]. Essentially,
CE can be used in place of traditional re-
versed-phase liquid chromatography for pro-
tein (as well as peptide) separation prior to
measurement by mass spectrometry. Similar
to a traditional set-up with a reversed-phase
column, CE can be directly coupled with
mass spectrometers in which the capillary
outlet is introduced into an ESI ion source,
resulting in ions than can be analyzed by the
mass spectrometer. Such analyses can be per-
formed  for  both  proteins  and  peptides
[19,20].
Two-dimensional gel electrophoresis.
Two-dimensional gel electrophoresis (2DGE)
is used often to separate highly complex pro-
tein samples. In the first dimension, the pro-
teins are typically separated by isoelectric
point. Traditionally, a polyacrylamide tube
gel is cast and a pH gradient is formed using
carrier ampholytes. More recently, immobi-
lized pH gradients on a polyacrylamide ma-
trix supported by a plastic backing have been
substituted for tube gels [21]. Unlike the tube
gels, which must be extruded from their glass
casting tubes, immobilized pH gradient (IPG)
strips have mechanical stability and are less
likely to break or stretch. In addition, IPG
strips can accommodate a wider range of pH
values, have improved reproducibility, and
are not as prone to pH drift (due to electro-
osmotic flow) as IEF tube gels. In the second
dimension, 2DGE typically separates proteins
based on mass via SDS-PAGE.
Although  sample  complexity  is  de-
creased compared to 1D SDS-PAGE as the
result of a second dimension of separation
in 2DGE, some pitfalls of this technique per-
sist.  Disadvantages  of  2DGE  include  (i)
spots  may  contain  multiple  proteins;  (ii)
poor spot resolution at high pI values; (iii)
very acidic and very basic proteins not being
well represented; (iv) very small or very
large proteins not being resolved on a stan-
dard gel; and (v) irreproducibility of gels
[22]. Two-dimensional gel electrophoresis
of membrane proteins is additionally ham-
pered by the potential insolubility of the hy-
drophobic portions of these proteins in IEF
focusing buffer, as well as the propensity for
precipitation at the isoelectric point of the
protein [23]. In addition, it has been deter-
mined that the technical variability of 2DGE
due to sample preparation, reagent sources,
experimenter variability, and staining meth-
ods accounts for a 20 percent to 30 percent
coefficient of variability [24]. The use of
IPG, standardized buffers, and large format
2D gels are among the improvements that
have overcome some of these pitfalls, al-
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proteomics [25].
Difference gel electrophoresis. Difference
gel electrophoresis (DiGE) resolves some of the
caveats associated with 2DGE. DiGE eliminates
gel-to-gel variation as two or three samples can
be conjugated to a different fluorescent dye
(Cy2, Cy3, or Cy5) and simultaneously analyzed
on a single gel [26]. For example, to compare
the protein profile of two samples, one sample
can be labeled with Cy5 dye and the second with
Cy3 dye. An optional third sample control may
consist of the two aforementioned samples com-
bined and labeled with Cy2 dye, which acts as an
internal standard. The Cy-series of dyes gener-
ally binds to lysine residues, although cysteine-
conjugating  dyes  and  other  chemistries  are
available [27-29]. All three samples are com-
bined and analyzed on an IPG strip for the first
dimension, and then separated by SDS-PAGE in
the second dimension. Following excitation at
different wavelengths (640 nm for Cy5 and 550
nm for Cy3), the Cy5-labeled proteins can be vi-
sualized at a particular wavelength (670 nm, red)
and Cy3 can be visualized under a second wave-
length (570 nm, green) [30]. Images taken at
each emission wavelength are then superim-
posed and differences can be qualitatively (pres-
ence or absence) and quantitatively (fluorescent
signal intensity) determined.
Gel  spots  corresponding  to  proteins
unique to one sample, or to proteins that over-
lap in both samples, can then be excised. These
gels spots can be in-gel enzymatically digested
and analyzed by mass spectrometry. The sensi-
tivity and dynamic range of DiGE is relatively
high  compared  to  other  staining  methods.
Quantitatively, a DiGE experiment can detect
0.5-1 fmol [31] of a single protein and has a dy-
namic range of five orders of magnitude, as op-
posed to silver stain, which has a detection limit
of 1 ng and a dynamic range of only two orders
of magnitude [25]. In summary, DiGE allows
for enhanced comparison of the protein profiles
of two or three samples and is compatible with
analysis by mass spectrometry.
Liquid chromatography-based fractionation
Liquid chromatography can be used to
separate proteins on the basis of hydropho-
bicity, ionic charge, or size, as well as to re-
move  substances  that  may  interfere  with
downstream analyses. The method most com-
monly used to fractionate proteins by their
hydrophobicity uses reversed-phase C4 or C8
resin. A similar chemistry using beads with
longer hydrocarbon chains, C18, is used to
resolve different populations of peptides. Elu-
tion with volatile organic solvents makes this
mode of chromatography ideal for mass spec-
trometric analysis [32]. However, these resins
are incompatible with certain detergents that
can compete for binding sites on the station-
ary phase (e.g., Triton X-100). Ion exchange
chromatography can be used for the removal
of detergent from samples. Resins can con-
sist of strong cation exchange (SCX), weak
cation exchange (WCX), strong anion ex-
change (SAX), weak anion exchange (WAX),
or mixed-bed, such as SCX-WAX [33]. Of
these, SCX is commonly used upstream of re-
versed-phase HPLC-MS/MS. The stationary
phase of SCX columns is negatively charged
and attracts positive ions (e.g., protonated
peptides). An increase in salt concentration or
pH of the mobile phase will promote elution
of the bound peptides. 
In some instances, size exclusion chro-
matography can also be used to fractionate
further a complex protein sample [34]. Affin-
ity chromatography methods also may be
useful when attempting to isolate specific
proteins or complexes of interest [35]. For
liquid chromatography fractionation of pro-
teins, caution should be taken that proteolytic
enzymes are properly deactivated with the
appropriate protease inhibitors prior to per-
forming  liquid  chromatography,  ensuring
sample integrity over prolonged periods dur-
ing chromatographic processing.
Proteolytic digestion 
Mass spectrometry can be performed on
either intact proteins (“top-down”) or on pep-
tides that originate from proteins digested by
a specific protease (“bottom-up”). To date,
proteomics of clinical samples has mainly fo-
cused on bottom-up approaches. Although
top-down proteomics may be a viable alter-
native for clinical sample analysis, we will
only focus on bottom-up approaches for the
63 Paulo et al: Mass spec.-based proteomics for translational researchpurpose of this review. Several excellent re-
views are available which explore top-down
proteomics [36-38].
Using the bottom-up approach, proteins
can either be digested in-gel or in-solution,
by a variety of strategies. When performing
in-gel digestions, gel slices or spots are ex-
cised and washed with an ammonium bicar-
bonate/acetonitrile solution to remove SDS
and buffer molecules from the gel slices. The
gel slices/spots are then dried and re-hydrated
with an ammonium bicarbonate solution con-
taining the appropriate protease [39]. 
Trypsin  is  typically  the  protease  of
choice as it has a high specificity, a low price
per unit, and is inherently stable under a wide
range of conditions, including 40 percent
acetonitrile and 2 M urea [40,41]. Addition-
ally, it cleaves at the C-terminal of arginine
and lysine residues, placing a highly basic
residue at this terminus, resulting in multiply
charged, or protonated, peptides. This phe-
nomena is important for larger species, as the
mass-to-charge ratio value (m/z) may be de-
creased enough to be within the mass range
of  the  instrument  [40].  Similarly,  Lys-C,
which cleaves only at lysine residues, is used
often for both in-gel and in-solution digests
[42]. For proteins having a low arginine and
lysine content, for example, those with mul-
tiple membrane spanning regions, other pro-
teases  may  be  substituted  for  trypsin.
Chymotrypsin,  for  example,  can  be  used
without any modifications to many standard
trypsin-based protocols [43]. Chymotrypsin
cleaves peptides at the carboxyl group of
tryptophan, tyrosine, phenylalanine, leucine,
and methionine. This protease has been used
successfully where trypsin had failed to give
an adequate spectra [44]. 
After digestion, peptides are extracted,
vacuum dried, and ready for analysis by
mass spectrometry. Alternatively, protocols
may include in-solution digestion in lieu of
GeLC, resulting in peptides that are frac-
tionated in a single dimension (reversed-
phase, strong cation exchange, or isoelectric
focusing) [45] or via MUDPIT (multidi-
mensional protein identification technology)
[46,47]. A novel method, filter-aided sample
preparation (FASP), in which filter units are
used to remove mass spectrometry-incom-
patible substances, may also be a promising
alternative to in-gel and in-solution digests
[48,49]. 
Peptide fractionation
Techniques similar to those utilized at
the protein level can be used to reduce sam-
ple complexity at the peptide level. Peptide
fractionation is particularly necessary when
in-solution digestions are performed, but can
also be valuable for in-gel or FASP protocols.
Orthogonal methods of separation include
high pH reversed-phase chromatography, ion
exchange chromatography, and/or isoelectric
focusing  prior  to  MALDI  or  LC-MS/MS
analysis. Several recent studies have com-
pared the various fractionation methods men-
tioned above [50-54]. However, such studies
investigated specific questions, and their par-
ticular strengths and weaknesses may not
apply to all study designs. When comparing
methods among laboratories, bias may also
be introduced as a result of experimenter ex-
pertise and familiarity with a frequently used
method. As with upstream sample prepara-
tion techniques, optimization may be needed
to establish standardized peptide fractionation
approaches for a particular workflow.
Following proteolytic digests and pep-
tide fractionation, substances that interfere
with downstream mass spectrometric acqui-
sition must be removed. Desalting is com-
monly accomplished using C18 resin, which
elutes peptides in a volatile solvent, or by
using strong cation exchange (SCX) resin,
particularly for detergent-containing sam-
ples, which can elute peptides with changes
in buffer pH. Desalting can be performed in
a spin column or in pipettes packed with the
aforementioned resin using, for example,
StageTips [55] or Zip-Tips [56]. Sample
clean-up can enhance signal, prevent con-
taminants from entering the mass spectrom-
eter, and prolong the longevity of analytical
columns which elute peptides into the mass
spectrometer. 
Quantitative proteomics
Although DiGE does overcome some
of the limitations of 2DGE, it still carries
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drophobic proteins, many of which are of
great importance in biomarker discovery. In
such cases, quantitative proteomics methods
may provide an unbiased approach to com-
prehensive proteome analysis. In cell cul-
tures,  stable  isotope  labels  may  be
introduced during cell growth to attain up to
100 percent labeling efficiency,  as is the
case when using SILAC (stable isotope la-
beling by amino acids in cell culture) [57].
Here, two cell states can be prepared, with
one state grown in media with heavy isotope
labeled  arginine  and/or  lysine.  The  two
states are combined and chromatographi-
cally separated to assess relative differences
and similarities in protein content. 
Such methods are not practical when in-
vestigating body fluids or tissue directly col-
lected  from  humans,  rather  they  are
primarily applicable to cell culture-based
systems and particularly those investigating
the cellular secretomes. Among the simplest
in vitro peptide labeling is 18O labeling, in
which heavy 18O-water is incorporated into
the peptides during directed proteolysis, i.e.,
with trypsin [58]. Alternatively, the isotope-
coded affinity tag (ICAT) technique can be
used, whereby samples are labeled at thiol
groups  with  either  of  two  reagents;  the
heavy  reagent  contains  eight  deuterium
atoms instead of eight hydrogen atoms, as in
the light form of the label. A more robust
method involves multiplexed isobaric tag la-
beling (e.g., isobaric tag for relative and ab-
solute quantitation: iTRAQ [59] or tandem
mass tag: TMT [60]) that can quantitatively
analyze up to eight diseased states, time
points, or samples in a single experiment.
These samples are then pooled and fraction-
ated by liquid chromatography prior to tan-
dem  mass  spectrometry  analysis.  The
fragmentation of the attached tag generates
low molecular mass reporter ions that can be
used to relatively quantify peptides and the
proteins from which they originate. 
In the absolute quantitation (AQUA)
method, a synthetic heavy-isotope-labeled
standard  peptide  is  introduced  into  cell
lysates at a known concentration and se-
lected reaction monitoring is used to detect
and quantitate the peptide of interest [61-
63]. These quantitative methods allow de-
tection of subtle changes in the proteome,
which would not have been possible using
only qualitative identification methods (i.e.,
presence vs. absence). 
Label-free  methods  for  quantitation
represent attractive alternatives [64], partic-
ularly for experiments that have been previ-
ously performed without labeling. With the
exception of SILAC, any of the aforemen-
tioned quantitative mass spectrometric tech-
niques  may  be  used  to  directly  analyze
clinical samples. 
Technological overview of 
mass spectrometry
Mass spectrometry has become an in-
dispensable analytical tool for the study of
proteomics. Using various bottom-up pro-
teomic approaches, specific proteins or pro-
tein complexes can be isolated, digested to
peptides, and identified by mass spectrome-
try. Known proteins can be validated, and
unknown proteins can be discovered with
this technique. Classical techniques such as
co-immunoprecipitation, reciprocal western
blotting and yeast-two-hybrid assays can
typically provide information on binary, or
at most ternary, interactions. Mass spec-
trometry, however, can discover protein-pro-
tein networks without any a priori suspicion
of interaction.
Mass spectrometric modalities
Various mass spectrometric modalities
are available for use in proteomic analysis
(Figure 2). The three main variable compo-
nents of a mass spectrometer are the ion
source, the mass analyzer, and the ion de-
tector. The ion source produces the ions that
are subsequently introduced into the gas
phase.  The  mass  analyzer  measures  the
mass-to-charge (m/z) ratio of the ionized
peptides.  The  two  ionization  techniques
commonly  used  for  mass  spectrometric
analyses of proteins and peptides are elec-
trospray ionization (ESI) and matrix-assisted
laser desorption/ionization (MALDI). ESI
and MALDI can be coupled with various
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quire an additional detector. The mass de-
tector records the abundance of ions at each
mass-to-charge value. As the number of ions
leaving the mass analyzer at a given time is
small,  amplification,  usually  by  electron
multipliers, is needed to acquire a measura-
ble signal [65]. The following sections pro-
vide an overview of technological aspects of
mass spectrometry and current application
thereof to proteomic analysis.
Tandem MS/MS and peptide sequencing 
A mass spectrometer also can be used to
identify  proteins  by  sequencing  peptides
using  a  procedure  called  tandem  MS  or
MS/MS. This process involves recording a
full mass spectrum and selecting a peak or
several peaks to be further fragmented. The
selection process is usually automated as a
threshold is set and MS/MS is performed on
any peak with an intensity greater than that
value. Peptide fragmentation can occur any-
where along the peptide backbone. Frag-
ments  produced  from  a  single  bond
fragmentation are denoted as a, b, c, x, y, and
z, depending on the covalent bonds which
are broken [66]. The ions y and b have preva-
lence  for  collision-induced  dissociation
(CID). Internal fragments and immonium
ions, as well as side chain fragmentation,
often also occur. Ions are selected and frag-
mented within a single quadrupole in instru-
ments such as a linear ion trap [67]. CID is
the most common method of generating tan-
dem mass spectra [68]. Modern mass spec-
trometric  instrumentation  allows  for
automated MS/MS analysis. For example, a
linear trap quadrupole instrument (LTQ) cou-
pled to either a MALDI or ESI source and an
Orbitrap or FT-ICR analyzer can select a de-
fined number of the most intense ion peaks
of a full scan MS-spectrum. These ions are
subsequently isolated and fragmented to ob-
tain sequence identification. A classic LTQ
can record these spectra at a rate of greater
than five scans per second, making this in-
strument ideal for high throughput assays
[69]. In addition, multistage fragmentation
(MSn) can reveal post-translational modifi-
cations, such as phosphorylation, as well as
structural characterization. Proteomic analy-
sis of clinical samples is not limited to a sin-
gle  mass  spectrometric  modality  for
biomarker discovery.
The mass accuracy and resolution of the
mass spectrometer are important factors that
enhance the signal-to-noise-ratio and lower
the  ion  detection  limit  [22].  When  opti-
mized, these factors result in a considerable
reduction of false positive and false negative
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Figure 2. Mass spectrometer modalities commonly used in proteomic research. A
mass spectrometer consists of three modules: 1) an ion source (ESI or MALDI), which ion-
izes the peptides to be analyzed, 2) a mass analyzer (or a combination of analyzers),
which can be used as a collision cell for fragmentation and/or sort the ions by their mass-
to-charge ratio, and 3) a detector which amplifies and quantifies the resulting signal.mass identifications, which is essential when
investigating data sets composed of many
different proteins with unknown identities.
Mass accuracy is the measurement of the ex-
actness of a recorded peptide mass to the
theoretical mass computed by in silico en-
zymatic digests on the primary sequence of
a target protein. The units of this measure
are often either Daltons or parts per million
(ppm). For comparison, time-of-flight mass
spectrometers provide within 2 to 5 ppm
mass accuracy, while quadrupole ion traps
provide accuracy in the range of 100 ppm
and above. However, modern mass analyz-
ers, such as the QTOF (quadrupole time-of-
flight),  Orbitrap,  or  FT-ICR  (Fourier
transform ion cyclotron resonance) instru-
ments can achieve sub-ppm mass accuracy
[70]. When analyzing samples of unknown
identity,  high  mass  accuracy  is  recom-
mended [67]. Resolution in mass spectrom-
etry is defined as the m/z value divided by
the peak width at half-maximum height [66].
In other words, it is the ability of the mass
spectrometer to differentiate between two
peaks and, thus, two different ions or frag-
ments, which is particularly useful for com-
plex samples [69]. In essence, reliable data
can be attained using an instrument with
high mass accuracy and high resolution. In
addition, high sensitivity is important for
low-abundance peptides. Data derived from
the fragmentations of peptide ions (MS/MS)
can  be  used  to  identify  amino  acid  se-
quences. However, the unambiguous identi-
fication of proteins from large data sets is
not trivial. 
Several computational algorithms have
been  developed  to  sequence  proteins  by
mass spectrometry, as the sheer number of
tandem MS/MS spectra precludes manual
interpretation of all spectra. Software pack-
ages and associated algorithms, such as SE-
QUEST [71], Mascot [72], Phenyx [73],
ProteinPilot [74], X!Tandem [75], and Pro-
teinProspector [76], search a given sequence
database for peptides with theoretical spec-
tra best matching the observed spectra and
subsequently assign these peptides to the
corresponding proteins. Both peptide and
proteins are scored, and thresholds can be
determined to estimate the quality of the
data [77,78]. False discovery rates (FDR)
are calculated typically to estimate erro-
neously identified proteins [79-81]. The au-
thors direct the reader to the references listed
above for more technical details concerning
the aforementioned software packages.
An APPLicATiOn OF MASS 
SPEcTROMETRY-BASEd PROTEOMicS
Our laboratory uses mass spectrometry-
based proteomics to study diseases of the ex-
ocrine pancreas, such as chronic pancreatitis
[82]. For a broader view of other methods
used in the proteomics of pancreatic disease,
we refer the reader to our recent review of
pancreatic fluid-based proteomics [82]. Also
for those readers interested in clinical sam-
ples of different origins, much detail is avail-
able in a recently published book [83], which
includes a chapter on body fluids [84]. We
have utilized several of the techniques de-
scribed herein to investigate chronic pancre-
atitis  using  secretin-stimulated,  ePFT
(endoscopic  pancreatic  function  test)-col-
lected pancreatic fluid [85]. Figure 3 illus-
trates our general methodology for pancreatic
fluid proteomic analysis. Standardized sam-
ple preparation conditions were first estab-
lished to minimize protein degradation, thus
maximizing yield [86,87]. Protein degrada-
tion of pancreatic fluid samples were of con-
siderable  concern  due  to  the  high
concentration of various proteases. In our
hands,  one-dimensional  GeLC-MS/MS
(SDS-PAGE gel coupled with liquid chro-
matography  tandem  mass  spectrometry)-
based methods produced more robust results
than DiGE analysis [88]. Using analogous
GeLC-MS/MS techniques, we have recently
investigated the proteomes of a pancreatic
stellate cell culture line [89]. In addition, we
have analyzed pancreas formalin-fixed paraf-
fin embedded tissue using in-solution diges-
tions  [90].  Following  our  established
protocols, trypsin-digested samples were sub-
jected  to  nanoESI,  after  which  an  LTQ-
FTICR  mass  spectrometer  was  used  to
measure peptide and fragment masses. Data
was primarily analyzed with MASCOT, al-
67 Paulo et al: Mass spec.-based proteomics for translational researchthough other software packages (e.g., Pro-
teomeDiscoverer and ProteinPilot) can also
be used. We commonly use Scaffold, GO
(gene ontology) analysis, and KEGG (Kyoto
Encyclopedia of Genes and Genomes) path-
ways to extract biological information from
our data. Using our GeLC-MS/MS strategy,
we have identified and classified more than
1,000 proteins in pancreatic fluid (manuscript
in  preparation).  Further  experimentation
using targeted assays, such as those described
above, will allow for the validation of our
biomarker discovery study. In summary, mass
spectrometry-based proteomics offers robust
and high throughput methods for biomarker
discovery and the development of hypothe-
ses for downstream investigations.




Careful and consistent sample handling
is essential for reproducible and robust mass
spectrometry results. The decision to use pro-
tease inhibitors and/or acidification must be
determined  for  a  particular  experiment  or
assay, as the use of such reagents may result in
irreversible modifications and may be detri-
mental to downstream analyses. For example,
several small molecule inhibitors, such as
PMSF (phenylmethylsulfonyl fluoride) and
AEBSF (4-(2-Aminoethyl) benzenesulfonyl
fluoride hydrochloride), have been shown to
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Figure 3. Optimized workflow for proteomic analysis of pancreatic fluid. Pancreatic
fluid is collected via ePFT. After particulates are removed by centrifugation, proteins are
extracted from the remaining supernatant with TCA. The protein pellet is reconstituted in
Laemmli buffer, alkylated, and reduced prior to analysis by SDS-PAGE. GeLC-MS/MS
analysis is performed, in which gel lanes are divided into smaller segments, which are in-
dividually in-gel tryptically digested. Digested peptides are eluted from a nanoflow C18 re-
versed-phased column into a mass spectrometer for accurate mass analysis. The
resulting mass spectra are processed to determine the peptides and eventually the pro-
teins from which these peptides originate.form  covalent  bonds  with  proteins  [91],
thereby changing pI and electrophoretic mo-
bility [92]. In addition, many protease in-
hibitor cocktails contain small molecule or
peptide inhibitors, which can interfere with
subsequent peptide ionization [93]. 
Standardization is a necessary compo-
nent of sample collection and mass spec-
trometry analysis. Only through standardized
sample  preparation  approaches  and  mass
spectrometry procedures can results be re-
produced. Although not currently feasible for
this relatively novel technology, future stan-
dardization of mass spectrometry techniques
will substantially improve the accuracy and
precision of diagnosing and following the
progression of diseases among individuals.
Some factors, however, cannot be controlled
in the laboratory. Confounders, such as age,
alcohol consumption, etiology, gender, race,
and smoking, must also be taken into consid-
eration as such differences may result in ad-
ditional variability. Cohorts should be chosen
carefully and matched as closely as possible.
Similarly, another aspect of sample prepa-
ration that requires further investigation is the
depletion of abundant proteins. Many human
body fluids and tissue, particularly those with
blood, have mg/mL levels of serum albumin
and ʱ2-macroglobulin. High concentrations of
these and other proteins may necessitate deple-
tion, possibly with antibody-conjugated mi-
crospheres, to achieve the sensitivity needed to
detect low abundance proteins; many important
differentially expressed proteins may be pres-
ent at very low levels in the cells. For examples,
cytokines are generally on the order of pg/mL in
human body fluids [94-97]. Targeted mass spec-
trometry assays, such as selected/multiple reac-
tion monitoring (SRM/MRM) assays, may be
required to detect such proteins and identify dif-
ferences in protein content between the normal
and diseased states. In addition, differential pro-
tein analysis may require quantitative methods,
as there may be basal levels of expression of a
targeted protein regardless of the disease.
OuTLOOK
The  combination  of  high-resolution
separation techniques and powerful mass
spectrometric analysis enables the acquisi-
tion of previously unattainable information
about the proteome of diseased patients and
healthy controls. The comprehensive analy-
sis of protein mixtures and the identification
of hundreds or thousands of proteins are
possible for clinical applications due to re-
cent developments in high-throughput mass
spectrometry [98-101]. Proteomics facili-
tates the elucidation of proteins that regulate
the pathogenesis of disease and facilitate the
discovery of clinically relevant biomarkers.
However, the quality of proteomic results
depends  heavily  on  the  methodology  by
which samples are prepared. Variations in
methods may introduce discrepancies that
can impede the progress of mass spectrom-
etry proteomics in translational research.
Further  standardization  of  methods  can
maximize protein extraction and minimize
the heterogeneity of samples by reducing
protein degradation.
Quantitative proteome profiling is key
for comparative analysis of proteins from
normal and diseased patients, as similar pro-
teins may be present in both states but at sig-
nificantly different concentrations. Without
quantitative information, the value of these
differentially abundant proteins as biomark-
ers may be overlooked. In comparative pro-
teomics, sample preparation is of utmost
importance as minor differences in experi-
mental and control samples may be instru-
mental to understanding the mechanisms
that  underlie  a  particular  disease.  Tech-
niques, such as those outlined herein, may
be useful in the study of quantitative differ-
ences between diseased and non-diseased
cohorts. Whereas the genome is relatively
stable and identical in all cells, the proteome
varies by organ, cell, subcellular location,
temporally,  and  due  to  stimuli,  such  as
changes in health, diet, and environment. In-
depth quantitative proteomic interrogation
of bodily fluids and tissue can assist in de-
termining if such variations are indeed a re-
sult of a particular disease state. 
Once biomarkers and molecular path-
ways of disease have been elucidated, efforts
must be focused on validation of these mass
spectrometry-based data. For example, dis-
69 Paulo et al: Mass spec.-based proteomics for translational researchease-specific biomarkers may be validated on
large numbers of patients and controls, while
longitudinal studies can be developed that ex-
amine  the  appearance,  disappearance,  or
modulation of expression over the course of
disease. In addition, biomolecular pathways
that may be altered during the course of dis-
ease progression can be investigated further
using the more controlled environment of cell
culture and/or animal models. With further
methodological and technological advances,
the mass spectrometry-based proteome analy-
sis of human body fluids and tissues offers
phenomenal potential for the detection, pre-
vention and treatment of diseases.
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